Outcome and risk factors for local recurrence after breast conserving surgery in patients affected by ductal carcinoma in situ

被引:5
|
作者
Tomasicchio, Giovanni [1 ]
Picciariello, Arcangelo [1 ]
Stucci, Luigia S. [2 ]
Panebianco, Annunziata [3 ]
Montanaro, Alda E. [4 ]
Cirilli, Alfredo [4 ]
Punzo, Clelia [1 ]
机构
[1] Univ Bari, Aldo Moro Univ, M Rubino Unit Gen Surg, Div Surg,Dept Emergency & Organ Transplant DETO, Piazza Giulio Cesare 11, I-70124 Bari, Italy
[2] Hosp Bari, Unit Med Oncol, Bari, Italy
[3] Univ Bari, Aldo Moro Univ, Chirurg VideoLaparoscop & Urgenza Unit Gen Surg, Div Surg,Dept Emergency & Organ Transplant DETO, Bari, Italy
[4] Hosp Bari, Unit Breast Surg, Bari, Italy
来源
MINERVA SURGERY | 2022年 / 77卷 / 06期
关键词
Carcinoma; intraductal; noninfiltrating; Breast neoplasms; Aftercare; Prognosis; NUYS PROGNOSTIC INDEX; CLASSIFICATION; MARKERS; CANCER; WOMEN;
D O I
10.23736/S2724-5691.22.09284-X
中图分类号
R61 [外科手术学];
学科分类号
摘要
BACKGROUND: Ductal carcinoma in situ (DCIS) is a tumor with long term survival and low local recurrence rate. Al-though the progression of these lesions is rare, the current guidelines recommend breast conservating surgery (BCS) with adjuvant radio and/or endocrine therapy, often resulting in an overtreatment for patients. The aim of this single-center study was to evaluate the long-term outcome of the breast conservating surgery of DCIS followed by adjuvant radio and/ or endocrine therapy and to identify prognostic factors associated with the risk of recurrence. METHODS: Patients treated for DCIS with BCS and radiation therapy between March 2006 and January 2019 were retrospectively reviewed using a prospectively maintained database. Analysis of the potential risk factors was performed to evaluate the risk of subsequent ipsilateral and contralateral recurrence. RESULTS: Out of 2894 patients, two hundred eighty-eight (10%) patients were treated for DCIS. After a median follow-up of 85 months (IQR 27-124), the incidence of recurrence was 6% (18 patients). Nine of them (3%) had an ipsilateral local recurrence (LR) with a median disease-free survival of 19 months (IQR 12-35). The remaining nine patients had contralateral metachronous breast cancer (CBC) with a median DFS of 29 months (IQR 14-36). Margin status, multifo-cality, hormone receptor status and Her-2/Basal-like subtype were identified as risk factors for the local recurrence with a OR of 5.58 (1.44-21.54), 7.46(1.89-24.48) 0.25 (0.06-0.96) and 4.86 (1.26-18.71) respectively. CONCLUSIONS: DCIS had been confirmed to have long term survival. Margin status, multifocality, hormone receptor status and Her-2/Basal-like subtype could be identified as reliable risk factors for the progression of the disease.
引用
收藏
页码:536 / 541
页数:6
相关论文
共 50 条
  • [31] Predicting factors of local recurrence in ductal carcinoma in situ of the breast
    Pumarola Brussosa, C.
    Castillo, H.
    Mula, C.
    Cebrecos, I.
    Caparros, X.
    Oses, G.
    Torras, I.
    Mension, E.
    EUROPEAN JOURNAL OF CANCER, 2022, 175 : S96 - S96
  • [32] Microinvasion is not associated with an increased risk of local recurrence in patients with ductal carcinoma in situ treated with breast-conserving therapy
    Rakovitch, E.
    Pignol, J-P
    Hanna, W.
    Chartier, C.
    Kahn, H.
    Wong, J.
    Paszat, L.
    RADIOTHERAPY AND ONCOLOGY, 2006, 80 : S69 - S69
  • [33] Local recurrence of ductal carcinoma in situ after conservative breast surgery: mammographic appearance
    El Khoury, M
    Mesurolle, B
    Cherel, P
    Guinebretiere, JM
    Plantet, MM
    de Maulmont, C
    Hagay, C
    JOURNAL DE RADIOLOGIE, 2006, 87 (05): : 555 - 559
  • [34] Local recurrence after ductal carcinoma in situ breast conserving treatment. Analysis of 195 cases
    Cutuli, B.
    Lemanski, C.
    Le Blanc-Onfroy, M.
    de Lafontan, B.
    Cohen-Solal-Le-Nir, C.
    Fondrinier, E.
    Mignotte, H.
    Giard, S.
    Charra-Brunaud, C.
    Auvray, H.
    Gonzague-Casabianca, L.
    Quetin, P.
    Fay, R.
    CANCER RADIOTHERAPIE, 2013, 17 (03): : 196 - 201
  • [35] How to make decisions in ductal carcinoma in situ? The first study of clinical applicability of the MSKCC ductal carcinoma in situ nomogram in the prediction of local recurrence risk after breast conserving surgery in a Brazilian cohort
    Marques, Larissa
    Carvalho, Heloisa
    Carvalho, Filomena
    Rodrigues, Luciana
    Aguiar, Fernando
    Barros, Alfredo
    CANCER RESEARCH, 2023, 83 (05)
  • [36] Nomogram for Risk of Relapse After Breast-Conserving Surgery in Ductal Carcinoma In Situ Reply
    Van Zee, Kimberly J.
    Rudloff, Udo
    Brogi, Edi
    Patil, Sujata
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (02) : E45 - E46
  • [37] Recurrence of Extensive Ductal Carcinoma in Situ Treated with Breast Conserving Surgery Compared to Mastectomy
    Que, J.
    Kim, D.
    Chen, L.
    Liu, R. Q.
    Zhang, M.
    Dingee, C. K.
    Warburton, R.
    McKevitt, E.
    Kuusk, U.
    Pao, J.
    Bazzarelli, A.
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (SUPPL 1) : S71 - S71
  • [38] New Developments in Assessing Risk of Local Recurrence in Patients with Ductal Carcinoma In Situ after Lumpectomy and Breast Radiation
    Lalani N.
    Nofech-Mozes S.
    Rakovitch E.
    Current Breast Cancer Reports, 2016, 8 (2) : 118 - 126
  • [39] Predictors of Recurrent Ductal Carcinoma In Situ after Breast-Conserving Surgery
    Kim, Jung Yeon
    Park, Kyeongmee
    Kang, Guhyun
    Kim, Hyun-Jung
    Gwak, Geumhee
    Shin, Young-Joo
    JOURNAL OF BREAST CANCER, 2016, 19 (02) : 185 - 190
  • [40] Local recurrence outcomes after breast conserving surgery and adjuvant radiotherapy in ductal carcinoma in situ of the breast and a comparison with ECOG E5194 study
    Akagunduz, Ozlem Ozkaya
    Ergen, Arzu
    Erpolat, Petek
    Gultekin, Melis
    Yildirim, Berna Akkus
    Parvizi, Murteza
    Ikiz, Didem
    Oksuz, Didem Colpan
    Onal, Cem
    Yildiz, Ferah
    Ozsaran, Zeynep
    BREAST, 2018, 42 : 10 - 14